Filing Details

Accession Number:
0001062993-22-013178
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-20 18:13:11
Reporting Period:
2022-05-18
Accepted Time:
2022-05-20 18:13:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661181 Organogenesis Holdings Inc. ORGO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1757373 S. Gary Gillheeney C/O Organogenesis Holdings Inc.
85 Dan Road
Canton MA 02021
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2022-05-18 86,531 $0.99 484,773 No 4 M Direct
Class A Common Stock Disposition 2022-05-18 86,531 $5.46 398,242 No 4 S Direct
Class A Common Stock Acquisiton 2022-05-19 118,504 $0.99 516,746 No 4 M Direct
Class A Common Stock Disposition 2022-05-19 118,504 $5.94 398,242 No 4 S Direct
Class A Common Stock Acquisiton 2022-05-20 58,654 $0.99 456,896 No 4 M Direct
Class A Common Stock Disposition 2022-05-20 58,654 $5.89 398,242 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (Right to Buy) Disposition 2022-05-18 86,531 $0.00 86,531 $0.99
Class A Common Stock Stock Option (Right to Buy) Disposition 2022-05-19 118,504 $0.00 118,504 $0.99
Class A Common Stock Stock Option (Right to Buy) Disposition 2022-05-20 58,654 $0.00 58,654 $0.99
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,251,073 2024-12-08 No 4 M Direct
1,132,569 2024-12-08 No 4 M Direct
1,073,915 2024-12-08 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.39 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $6.11, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $6.04, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
  5. 100% of the shares subject to the option are fully vested and exercisable.